Information Provided By: 
Fly News Breaks for May 30, 2018
RVNC
May 30, 2018 | 06:18 EDT
Mizuho analyst Difei Yang recommends using the weakness yesterday in shares of Revance Therapeutics as a buying opportunity. While the resignation of CFO Lauren Silvernail was unexpected, Revance is already in search of a new CFO and CEO Dan Brown is confident that a good candidate would be announced in the next six months, Yang tells investors in a research note after speaking to Brown. The analyst reiterates a Buy rating on Revance with a $48 price target.
News For RVNC From the Last 2 Days
There are no results for your query RVNC
